Listen

Search

American Academy of Optometry (AAOpt) Annual Meeting 2020

Virtual Congress

ProQR participation in the American Academy of Optometry Annual Meeting 2020

Oktober 07, 2020
Oligonucleotide and Precision Therapeutics (OPT) Congress

Congress

ProQR presentation and panel session at the Oligonucleotide and Precision Therapeutics (OPT) Congress

März 14, 2023
Structure-based computational approach for optimizing oligonucleotides for A-to-I editing

Poster

Applicability of a structure-based modelling approach as a tool for in silico screening of oligonucleotides for targeted RNA editing presented at Oligonucleotide Therapeutics Society (OTS) 2018 by Julien Boudet

September 30, 2018
ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Press release

LEIDEN, The Netherlands, Sept. 23, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

September 23, 2014
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Press release

… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, the Netherlands … available on the SEC's website, located at www.sec.gov . Copies of the final prospectus supplement and the …

Oktober 18, 2019
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

September 11, 2018
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

April 05, 2021
Privacy

Seite

This privacy statement informs our website visitors on what, for what purposes and how we process personal data.
ProQR founding story

Seite

When our CEO, Daniel A. de Boer, knew his newborn son had an incurable rare disease, he founded ProQR to help people like his son. Learn more.
Presentations & Publications

Seite

Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.

Search

Results (1 to 10 of 155)